Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025

Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a biopharmaceutical company based in Rehovot, Israel, and Hoboken, New Jersey, is scheduled to report its financial results for the third quarter and the nine months ending September 30, 2025, on November 10, 2025. The announcement will precede the opening of U.S. financial markets. Following the release, Kamada management will host a conference call at 8:30 AM Eastern Time to discuss the financial outcomes and address inquiries from the investment community. Participants can join via phone or through a live webcast link provided by the company.

Kamada is recognized for its portfolio of specialty plasma-derived products aimed at treating rare and serious conditions. These include six FDA-approved products such as KEDRAB® and GLASSIA®, and the company is actively working on enhancing its market reach and financial performance through several strategic initiatives. Kamada's growth strategy encompasses four key pillars: expanding organic growth in commercial activities, pursuing new business development and collaborations, enhancing plasma collection operations, and advancing its research and development efforts.

Furthermore, the company is focusing on increasing its plasma collection capabilities to meet rising demand and support its product pipeline, which includes the promising Inhaled AAT, currently in a pivotal Phase 3 clinical trial. FIMI Opportunity Funds controls approximately 38% of Kamada's outstanding shares, underlining the firm’s strategic backing. This forthcoming financial announcement and subsequent discussions are crucial for investors and stakeholders eager to gauge the company’s trajectory in the biopharmaceutical sector.

Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a key player in the biopharmaceutical sector specializing in plasma-derived therapies, is poised to release its third quarter and nine-month financial results on November 10, 2025. This announcement presents a critical opportunity for investors to reassess the stock's market potential, given the company's strategic growth pillars.

Investors should closely monitor the upcoming financial results as they will provide insights into Kamada’s organic growth driven by its robust portfolio, which features six FDA-approved specialty products. Particularly noteworthy is the company’s recent expansion in both its plasma collection operations and its focus on securing new business development agreements. This dual approach is expected to bolster revenue, particularly with existing market dynamics that favor innovative therapies for rare conditions.

The market's reaction will likely depend significantly on the performance details shared during the management's conference call scheduled for 8:30 AM EST on the results release date. This is when management could provide guidance on both the financial performance metrics and the progress of key initiatives, including the InnovAATe clinical trial for Inhaled AAT, which aims to address significant unmet medical needs.

In assessing Kamada's stock, potential investors should consider the current price action and trading volume leading up to the earnings release. A spike in trading or volatility may signal investor sentiment ahead of the results. Moreover, with FIMI Opportunity Funds holding approximately 38% of the company's shares, their strategic decisions could also influence the stock's trajectory.

Overall, Kamada's upcoming financial results could represent a pivotal moment, making it advisable for shareholders and potential investors to remain vigilant for updates on operational achievements and future growth plans.